U.S. markets close in 1 hour 40 minutes
  • S&P 500

    4,181.95
    +11.53 (+0.28%)
     
  • Dow 30

    34,174.10
    +138.11 (+0.41%)
     
  • Nasdaq

    14,033.32
    -5.45 (-0.04%)
     
  • Russell 2000

    2,260.22
    +3.15 (+0.14%)
     
  • Crude Oil

    63.25
    -0.21 (-0.33%)
     
  • Gold

    1,778.80
    +12.00 (+0.68%)
     
  • Silver

    26.08
    +0.12 (+0.45%)
     
  • EUR/USD

    1.1977
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.5760
    +0.0460 (+3.01%)
     
  • GBP/USD

    1.3830
    +0.0046 (+0.33%)
     
  • USD/JPY

    108.7800
    +0.0640 (+0.06%)
     
  • BTC-USD

    61,519.08
    -1,205.62 (-1.92%)
     
  • CMC Crypto 200

    1,385.75
    -5.96 (-0.43%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,683.37
    +40.68 (+0.14%)
     

ElectroCore's Shares Are Trading Higher After Australia Ok'd Vagus Nerve Stimulator For Headaches

Vandana Singh
·1 min read

The Australian Therapeutic Goods Administration has approved ElectroCore Inc's (NASDAQ: ECOR) gammaCore Sapphire family of products, including a non-invasive vagus nerve stimulator (nVNS) for primary headache disorders.

  • Concurrently, the company has entered into an agreement with Medistar2 PTY Limited, whereby Medistar will serve as the exclusive distributor of the gammaCore Sapphire nVNS in Australia.

  • The initial term of the agreement is three years.

  • Medistar, an independent medical device distributor, will officially launch the gammaCore Sapphire at the 2021 ANZHS Headache Annual Scientific Meeting, held on March 13-14. 

  • Last week, the company completed enrollment in a study evaluating the effect of nVNS on respiratory symptoms due to COVID-19.

  • Price Action: ECOR shares surged 58% at $3.43 in premarket trading on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.